Empliciti® (elotuzumab) is the first monoclonal antibody approved to treat multiple myeloma. It is given intravenously (into the vein, IV) and taken in combination with the medicines Revlimid® (lenalidomide) and dexamethasone, in people who have received 1 to 3 prior treatments for their disease. It is also approved for use in combination with Pomalyst® and dexamethasone in patients with myeloma who have received at least 2 prior therapies including Revlimid and a proteasome inhibitor.

How Is It Used?

Unlike traditional chemotherapy treatments, Empliciti is a new type of immunotherapy that works with a patient’s own immune system to fight multiple myeloma in two ways:

  • Empliciti activates a key type of white blood cell in your immune system called a natural killer (NK) cell.
  • Empliciti identifies myeloma cells so they are more easily recognized by NK cells. That way, activated NK cells can find and destroy those myeloma cells.

Possible Side Effects of Empliciti, Revlimid, and Dexamethasone

Empliciti with Revlimid and dexamethasone adds little or no toxicity over Revlimid/dexamethasone alone. As with other monoclonal antibodies, Empliciti may cause infusion reactions that can occur during the IV infusion or within 24 hours after the infusion. Most infusion reactions occur with the first dose, and include fever, chills, chest pain, rash, trouble breathing, and dizziness or lightheadedness. Medications are given before each dose of Empliciti to reduce the risk of infusion reactions. Reactions can also be managed by slowing or stopping the infusion.

Other Common Side Effects of Empliciti, Revlimid, and dexamethasone

  • low white cell count
  • anemia (low red blood cell count)
  • low platelets (the cells that enable blood to clot after an injury)
  • fatigue
  • diarrhea
  • fever
  • constipation
  • infections
  • muscle spasms
  • decreased appetite

Empliciti Dose and Schedule

*prescribing information 2015

Clinical Trials

Clinical Trial Fact Sheet ELOQUENT-1 trial

Active, Not Recruiting

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma.

Clinical Trial Fact Sheet ELOQUENT-2 trial

Active, Not Recruiting

Phase III Randomized, Open-label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

Elotuzumab Open Clinical Trials is a registry of federally and privately supported clinical trials conducted in the U.S. and around the world. gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from healthcare professionals.


The International Myeloma Foundation medical and editorial content team

Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website. 

Last Medical Content Review: September 1, 2021

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.